Current Gastroenterology Reports

, Volume 13, Issue 1, pp 78–86 | Cite as

The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection

  • Brian L. PearlmanEmail author


The hypothesis that host genetics play an essential role in the ability not only to clear acute hepatitis C infection but also to achieve sustained virologic response (SVR) to interferon (IFN)-based therapy has been proved with the recent discovery of two single-nucleotide polymorphisms on chromosome 19. Variants in the minor allele rs8099917 and the proximate polymorphism rs12979860, 3 kb upstream of the interleukin (IL)-28B gene, which encodes the endogenous antiviral cytokine IFN-λ, are associated with SVR and with natural viral clearance. The disparate frequencies of these alleles in ethnic groups worldwide may well explain differing rates of SVR among them. The test for one of these polymorphisms is now commercially available and can serve as a powerful predictor of a patient’s chance of achieving SVR. Perhaps more importantly, the test can help the clinician personally tailor the duration and even the type of therapy that is most appropriate for an individual patient, newly or chronically infected with the hepatitis C virus.


Hepatitis C Acute hepatitis C Chronic hepatitis C Viral hepatitis IL-28 polymorphisms Genome-wide association studies Single-nucleotide polymorphisms 



Conflicts of interest: B. Pearlman—speakers’ bureau for Merck.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35–47.Google Scholar
  2. 2.
    Kim WR: The burden of hepatitis C in the United States. Hepatology 2002, 36(5 Suppl 1):S30–S34.CrossRefPubMedGoogle Scholar
  3. 3.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.CrossRefPubMedGoogle Scholar
  4. 4.
    Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.CrossRefPubMedGoogle Scholar
  5. 5.
    Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and causcasian patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470–477.CrossRefPubMedGoogle Scholar
  6. 6.
    • Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399–401. This landmark paper was the first to describe the polymorphism, rs12979860, near the IL-28B gene that is highly predictive of a patient’s achieving SVR, and may well become an essential component in clinical decision making regarding hepatitis C therapy. CrossRefPubMedGoogle Scholar
  7. 7.
    • Manolio TA: Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010, 363:166–176. This succinct review paper describes the technical and clinical aspects of the use of the genomewide association study and its success in identifying genetic associations with complex traits. CrossRefPubMedGoogle Scholar
  8. 8.
    Peason TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335–1344.CrossRefGoogle Scholar
  9. 9.
    Christiansen K, Murray JC: What genome-wide association studies can do for medicine. N Engl J Med 2007, 356:1094–1097.CrossRefGoogle Scholar
  10. 10.
    Tanaka Y, Nishida N, Sugiyama M, et al.: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009, 41:1105–1109.CrossRefPubMedGoogle Scholar
  11. 11.
    Suppiah V, Moldovan M, Ahlenstiel G, et al.: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100–1104.CrossRefPubMedGoogle Scholar
  12. 12.
    Marcello T, Grakoui A, Barba-Spaeth G, et al.: Interferons gamma and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887–1898.CrossRefPubMedGoogle Scholar
  13. 13.
    Gad HH, Dellgren C, Hamming OJ, et al.: Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009, 284:20869–20875.CrossRefPubMedGoogle Scholar
  14. 14.
    Ank N, Paludan SR: Type III interferons: new layers of complexity in innate antiviral immunity. Biofactors 2009, 35:82–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Pagliaccetti NE, Eduardo R, Kleinstein SH, et al.: Interleukin-29 (inteferon-lambda1) functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C replication. J Biol Chem 2008, 283:30079–30089.CrossRefPubMedGoogle Scholar
  16. 16.
    Barrera JM, Bruguera M, Ercilla MG, et al.: Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995, 21:639–644.CrossRefPubMedGoogle Scholar
  17. 17.
    Farci P, Shimoda A, Coiana A, et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339–344.CrossRefPubMedGoogle Scholar
  18. 18.
    Diepolder HM, Zachoval R, Hoffmann RM, et al.: Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346:1006–1007.CrossRefPubMedGoogle Scholar
  19. 19.
    Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450–456.CrossRefPubMedGoogle Scholar
  20. 20.
    Alric L, Fort M, Izopet J, et al.: Genes of the major histocompatibility complex class II influence the outcome of hepatitis C infection. Gastroenterology. 1997, 113:1675–1681.CrossRefPubMedGoogle Scholar
  21. 21.
    Thursz M, Yallop R, Goldin R, et al.: Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Lancet 1999, 354:2094–205.CrossRefGoogle Scholar
  22. 22.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al.: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580–593.CrossRefPubMedGoogle Scholar
  23. 23.
    • Thomas DL, Thio CL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798–801. This article describes the first study to demonstrate the IL28B polymorphism’s association with resolution of acute HCV infection among Caucasians of European ancestry and African Americans. CrossRefPubMedGoogle Scholar
  24. 24.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.CrossRefPubMedGoogle Scholar
  25. 25.
    Villano SA, Vlahov D, Nelson KE, et al.: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999, 29:908–914.CrossRefPubMedGoogle Scholar
  26. 26.
    Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al.: Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33–37.CrossRefPubMedGoogle Scholar
  27. 27.
    Rauch A, Kutalik Z, Descombes P, et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide study. Gastroenterology 2010, 138:1338–1345.CrossRefPubMedGoogle Scholar
  28. 28.
    Wiese M, Berr F, Lafrenz M, et al.: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000, 32:91–96.CrossRefPubMedGoogle Scholar
  29. 29.
    • Tillman HL, Thompson AJ, Patel K, et al.: A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice. Gastroenterology 2010 (Epub ahead of print). Using the cohort of young German women who had received contaminated immunoglobulin, the authors of this study were able to evaluate the IL-28B polymorphism in acute infection. The analysis is particularly important because it was able to study host genetics in a single-source outbreak at the time of infection where ethnic background and viral sequence diversity are minimal. Google Scholar
  30. 30.
    Gerlach JT, Diepolder HM, Zachoval R, et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80–88.CrossRefPubMedGoogle Scholar
  31. 31.
    Grebely J, Petoumenos K, Hellard M, et al.: Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216–1224.CrossRefPubMedGoogle Scholar
  32. 32.
    Santantonio T, Sinisi E, Guastadisegni A, et al.: Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003, 35:104–113.CrossRefPubMedGoogle Scholar
  33. 33.
    Muir AJ, Bornstein JD, Killenberg PG, et al.: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004, 350:2265–2271.CrossRefPubMedGoogle Scholar
  34. 34.
    McCarthy JJ, Li JH, Thompson A, et al.: Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307–2314.CrossRefPubMedGoogle Scholar
  35. 35.
    Honda M, Sakai A, Yamashita T, et al.: Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C. Gastroenterology 2010, 139:499–509.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen L, Borozan I, Feld J, et al.: Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437–1444.CrossRefPubMedGoogle Scholar
  37. 37.
    Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al.: Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008, 105:7034–7039.CrossRefPubMedGoogle Scholar
  38. 38.
    Urban TJ, Thompson AJ, Bradrick S, et al.: IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in chronic hepatitis C patients. Hepatology 2010 (Epub ahead of print).Google Scholar
  39. 39.
    Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652.CrossRefPubMedGoogle Scholar
  40. 40.
    Poordad F, Reddy KR, Martin P: Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008, 46:78–84.CrossRefPubMedGoogle Scholar
  41. 41.
    • Thompson AJ, Muir AJ, Sulkowski MS, et al.: Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120–129. These investigators confirmed that the IL-28B polymorphism is the strongest baseline predictor of SVR in genotype 1-infected patients treated with peginterferon-ribavirin. They demonstrated that the favorable IL-28B genotype is associated with improved viral kinetics and increased rate of RVR relative to those with the unfavorable genotype. The paper is the most clinically relevant to date among the papers pertaining to chronic HCV treatment and the IL-28B polymorphism. CrossRefPubMedGoogle Scholar
  42. 42.
    Mangia A, Thompson AJ, Santoro R, et al.: IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821–827.CrossRefPubMedGoogle Scholar
  43. 43.
    Mangia A, Santoro R, Minerva N, et al.: Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609–2617.CrossRefPubMedGoogle Scholar
  44. 44.
    Akuta N, Suzuki F, Hirakawa M, et al.: Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421–429.CrossRefPubMedGoogle Scholar
  45. 45.
    Stattermayer AF, Stauber R, Hofer H, et al.: Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2010 (Epub ahead of print).Google Scholar
  46. 46.
    Zeuzem S, Buti M, Ferenci P, et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97–103.CrossRefPubMedGoogle Scholar
  47. 47.
    Rallon NI, Naggie S, Benito JM, et al.: Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23–F29.CrossRefPubMedGoogle Scholar
  48. 48.
    Pineda JA, Caruz A, Rivero A, et al.: Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010, 51:788–795.CrossRefPubMedGoogle Scholar
  49. 49.
    Muir AJ, Shiffman ML, Zaman A, et al.: Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822–832.CrossRefPubMedGoogle Scholar
  50. 50.
    Kraus MR, Al-Taie O, Schafer A, et al.: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279–1286.CrossRefPubMedGoogle Scholar
  51. 51.
    Fellay J, Thompson AJ, Ge D, et al.: ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010, 464:405–408.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Center for Hepatitis CAtlanta Medical CenterAtlantaUSA
  2. 2.Medical College of GeorgiaAugustaUSA
  3. 3.Emory School of MedicineAtlantaUSA

Personalised recommendations